

PRESS RELEASE

JHL Awarded top 20 Deloitte 2017 Asia Technology Fast 500™

13DEC2017

JHL Biotech, Inc. (“JHL”, 6540. TWO) was awarded a top 20 ranking in Deloitte Touche Tohmatsu Limited’s 2017 Asia Technology Fast 500™ list. This annual ranking compares the fastest growing Asia Pacific companies in the life sciences, software and hardware tech sectors, clean technology, media, and communications.

The company’s ranking (#19) makes it the only life sciences company and one of only two Taiwanese companies in the top 20.

JHL’s President & CEO, Racho Jordanov remarked, “We are honored and humbled to receive this recognition. That we placed atop our life sciences peers speaks for itself. But that we placed so well against great companies in industries with more modest capital requirements, yet faster growth rates, is a testament to our business model and the talent and dedication of JHL’s employees.”

End

Media Contact:

Jill Liu, Amber Chen

Phone: +886 3-658-3899

jliu@jhlbiotech.com, achen@jhlbiotech.com

About JHL Biotech

JHL Biotech Inc. (Stock Code: 6540.TWO) is a biopharmaceutical firm founded by a group of biopharmaceutical industry veterans. JHL’s investors include premier financial firms and strategic partners such as Kleiner Perkins Caufield & Byers, Biomark Capital, Milestone Capital, Sanofi, and Sequoia Capital. JHL is developing proposed biosimilars to rituximab, dornase alfa, bevacizumab, and trastuzumab. JHL1101, JHL’s proposed rituximab biosimilar, is undergoing clinical trials in the European Union. In addition to biosimilars, JHL also co-develops innovative new molecules and provides contract manufacturing services to select clients. For more information, please visit www.jhlbiotech.com.